Propanc Biopharma Inc (PPCB) – This company focuses on treatments for pancreatic, ovarian, and colorectal cancer. They are working to prevent the recurrence and metastasis of tumors using pancreatic proenzymes that target and eradicate cancer stem cells. This proenzyme therapy is based on the research that enzymes stimulate reactions in the body, specifically enzymes secreted by the pancreas. These pancreatic enzymes may represent the body’s first defense against cancer.
This is a penny stock to watch. They were able to showcase their findings to experts and researchers at the EORTC-PAMM meeting where their cutting-edge opportunities in cancer drug development were well received. Their “research highlights future potential clinical applications of our lead product candidate, PRP, as a pre-treatment with current standard treatment approaches and existing innovative cancer therapies”. PRP is not the only product currently in their pipeline.
Visit http://www.propanc.com to learn more.